{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:36:47Z","timestamp":1793720207933,"version":"4.6.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["NS090244 and NS115094"],"award-info":[{"award-number":["NS090244 and NS115094"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013077","name":"National Science and Technology Planning Project","doi-asserted-by":"publisher","award":["2020YFH0148"],"award-info":[{"award-number":["2020YFH0148"]}],"id":[{"id":"10.13039\/501100013077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The mechanisms underlying lesions of dopaminergic (DA) neurons, an essential pathology of Parkinson\u2019s disease (PD), are largely unknown, although oxidative stress is recognized as a key factor. We have previously shown that the pro-oxidative aldehyde acrolein is a critical factor in PD pathology, and that acrolein scavenger hydralazine can reduce the elevated acrolein, mitigate DA neuron death, and alleviate motor deficits in a 6-hydroxydopamine (6-OHDA) rat model. As such, we hypothesize that a structurally distinct acrolein scavenger, dimercaprol (DP), can also offer neuroprotection and behavioral benefits.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>DP was used to lower the elevated levels of acrolein in the basal ganglia of 6-OHDA rats. The acrolein levels and related pathologies were measured by immunohistochemistry. Locomotor and behavioral effects of 6-OHDA injections and DP treatment were examined using the open field test and rotarod test. Pain was assessed using mechanical allodynia, cold hypersensitivity, and plantar tests. Finally, the effects of DP were assessed in vitro on SK-N-SH dopaminergic cells exposed to acrolein.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>DP reduced acrolein and reversed the upregulation of pain-sensing transient receptor potential ankyrin 1 (TRPA1) channels in the substantia nigra, striatum, and cortex. DP also mitigated both motor and sensory deficits typical of PD. In addition, DP lowered acrolein and protected DA-like cells in vitro. Acrolein\u2019s ability to upregulate TRPA1 was also verified in vitro using cell lines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results further elucidated the acrolein-mediated pathogenesis and reinforced the critical role of acrolein in PD while providing strong arguments for anti-acrolein treatments as a novel and feasible strategy to combat neurodegeneration in PD. Considering the extensive involvement of acrolein in various nervous system illnesses and beyond, anti-acrolein strategies may have wide applications and broad impacts on human health.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40035-021-00239-0","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T04:03:05Z","timestamp":1619582585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson\u2019s disease: implication of acrolein and TRPA1"],"prefix":"10.1186","volume":"10","author":[{"given":"Liangqin","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhou","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth A.","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7297-9428","authenticated-orcid":false,"given":"Riyi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"239_CR1","doi-asserted-by":"crossref","unstructured":"Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382\u201397.\u00a0","DOI":"10.1016\/S1474-4422(09)70062-6"},{"issue":"8753","key":"239_CR2","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/0140-6736(91)92989-F","volume":"337","author":"Y Agid","year":"1991","unstructured":"Agid Y. Parkinson's disease:pathophysiology. Lancet. 1991;337(8753):1321\u20134. https:\/\/doi.org\/10.1016\/0140-6736(91)92989-F.","journal-title":"Lancet."},{"issue":"1","key":"239_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27(1):27\u201342. https:\/\/doi.org\/10.1111\/ene.14108.","journal-title":"Eur J Neurol"},{"issue":"50","key":"239_CR4","doi-asserted-by":"publisher","first-page":"34887","DOI":"10.1074\/jbc.M805682200","volume":"283","author":"X Liu","year":"2008","unstructured":"Liu X, Yamada N, Maruyama W, Osawa T. Formation of dopamine adducts derived from brain polyunsaturated fatty acids: mechanism for Parkinson disease. J Biol Chem. 2008;283(50):34887\u201395. https:\/\/doi.org\/10.1074\/jbc.M805682200.","journal-title":"J Biol Chem"},{"issue":"3\u20134","key":"239_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/BF01249445","volume":"38","author":"P Riederer","year":"1976","unstructured":"Riederer P, Wuketich S. Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm. 1976;38(3\u20134):277\u2013301. https:\/\/doi.org\/10.1007\/BF01249445.","journal-title":"J Neural Transm"},{"issue":"7","key":"239_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/0166-2236(90)90112-N","volume":"13","author":"MJ Zigmond","year":"1990","unstructured":"Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 1990;13(7):290\u20136. https:\/\/doi.org\/10.1016\/0166-2236(90)90112-N.","journal-title":"Trends Neurosci"},{"issue":"5","key":"239_CR7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","volume":"8","author":"KR Chaudhuri","year":"2009","unstructured":"Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464\u201374. https:\/\/doi.org\/10.1016\/S1474-4422(09)70068-7.","journal-title":"Lancet Neurol"},{"issue":"10","key":"239_CR8","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1474-4422(08)70214-X","volume":"7","author":"SH Fox","year":"2008","unstructured":"Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol. 2008;7(10):927\u201338. https:\/\/doi.org\/10.1016\/S1474-4422(08)70214-X.","journal-title":"Lancet Neurol"},{"issue":"6","key":"239_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13031","volume":"18","author":"BG Trist","year":"2019","unstructured":"Trist BG, Hare DJ, Double KL. Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease. Aging Cell. 2019;18(6):e13031. https:\/\/doi.org\/10.1111\/acel.13031.","journal-title":"Aging Cell"},{"issue":"11","key":"239_CR10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ncpneuro0924","volume":"4","author":"C Henchcliffe","year":"2008","unstructured":"Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008;4(11):600\u20139. https:\/\/doi.org\/10.1038\/ncpneuro0924.","journal-title":"Nat Clin Pract Neurol"},{"key":"239_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.mcn.2018.01.006","volume":"88","author":"A Ambaw","year":"2018","unstructured":"Ambaw A, Zheng L, Tambe MA, Strathearn KE, Acosta G, Hubers SA, et al. Acrolein-mediated neuronal cell death and alpha-synuclein aggregation: implications for Parkinson's disease. Mol Cell Neurosci. 2018;88:70\u201382. https:\/\/doi.org\/10.1016\/j.mcn.2018.01.006.","journal-title":"Mol Cell Neurosci"},{"key":"239_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.mcn.2019.06.004","volume":"98","author":"G Acosta","year":"2019","unstructured":"Acosta G, Race N, Herr S, Fernandez J, Tang J, Rogers E, et al. Acrolein-mediated alpha-synuclein pathology involvement in the early post-injury pathogenesis of mild blast-induced Parkinsonian neurodegeneration. Mol Cell Neurosci. 2019;98:140\u201354. https:\/\/doi.org\/10.1016\/j.mcn.2019.06.004.","journal-title":"Mol Cell Neurosci"},{"key":"239_CR13","first-page":"22","volume":"2","author":"R Shi","year":"2006","unstructured":"Shi R, Luo L. The role of acrolein in spinal cord injury. Appl Neurol. 2006;2:22\u20137.","journal-title":"Appl Neurol"},{"issue":"1","key":"239_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/mnfr.200700412","volume":"52","author":"JF Stevens","year":"2008","unstructured":"Stevens JF, Maier CS. Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease. Mol Nutr Food Res. 2008;52(1):7\u201325. https:\/\/doi.org\/10.1002\/mnfr.200700412.","journal-title":"Mol Nutr Food Res"},{"issue":"6","key":"239_CR15","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/j.1471-4159.2009.06395.x","volume":"111","author":"K Hamann","year":"2009","unstructured":"Hamann K, Shi R. Acrolein scavenging: a potential novel mechanism of attenuating oxidative stress following spinal cord injury. J Neurochem. 2009;111(6):1348\u201356. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06395.x.","journal-title":"J Neurochem"},{"issue":"9","key":"239_CR16","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/mnfr.201100217","volume":"55","author":"R Shi","year":"2011","unstructured":"Shi R, Rickett T, Sun W. Acrolein-mediated injury in nervous system trauma and diseases. Mol Nutr Food Res. 2011;55(9):1320\u201331. https:\/\/doi.org\/10.1002\/mnfr.201100217.","journal-title":"Mol Nutr Food Res"},{"issue":"7","key":"239_CR17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.4103\/1673-5374.131564","volume":"9","author":"J Park","year":"2014","unstructured":"Park J, Muratori B, Shi R. Acrolein as a novel therapeutic target for motor and sensory deficits in spinal cord injury. Neural Regen Res. 2014;9(7):677\u201383. https:\/\/doi.org\/10.4103\/1673-5374.131564.","journal-title":"Neural Regen Res"},{"issue":"1","key":"239_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0891-5849(91)90192-6","volume":"11","author":"H Esterbauer","year":"1991","unstructured":"Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11(1):81\u2013128. https:\/\/doi.org\/10.1016\/0891-5849(91)90192-6.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"239_CR19","doi-asserted-by":"publisher","first-page":"45741","DOI":"10.1038\/srep45741","volume":"7","author":"YT Wang","year":"2017","unstructured":"Wang YT, Lin HC, Zhao WZ, Huang HJ, Lo YL, Wang HT, et al. Acrolein acts as a neurotoxin in the nigrostriatal dopaminergic system of rat: involvement of alpha-synuclein aggregation and programmed cell death. Sci Rep. 2017;7(1):45741. https:\/\/doi.org\/10.1038\/srep45741.","journal-title":"Sci Rep"},{"issue":"2","key":"239_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/jnc.12628","volume":"129","author":"J Park","year":"2014","unstructured":"Park J, Zheng L, Marquis A, Walls M, Duerstock B, Pond A, et al. Neuroprotective role of hydralazine in rat spinal cord injury-attenuation of acrolein-mediated damage. J Neurochem. 2014;129(2):339\u201349. https:\/\/doi.org\/10.1111\/jnc.12628.","journal-title":"J Neurochem"},{"issue":"3","key":"239_CR21","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/j.1471-4159.2007.05002.x","volume":"104","author":"K Hamann","year":"2008","unstructured":"Hamann K, Nehrt G, Ouyang H, Duerstock B, Shi R. Hydralazine inhibits compression and acrolein-mediated injuries in ex vivo spinal cord. J Neurochem. 2008;104(3):708\u201318. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.05002.x.","journal-title":"J Neurochem"},{"issue":"1","key":"239_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/jnr.20862","volume":"84","author":"P Liu-Snyder","year":"2006","unstructured":"Liu-Snyder P, Borgens RB, Shi R. Hydralazine rescues PC12 cells from acrolein-mediated death. J Neurosci Res. 2006;84(1):219\u201327. https:\/\/doi.org\/10.1002\/jnr.20862.","journal-title":"J Neurosci Res"},{"issue":"1","key":"239_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1179\/rer.2000.5.1.47","volume":"5","author":"PC Burcham","year":"2000","unstructured":"Burcham PC, Kerr PG, Fontaine F. The antihypertensive hydralazine is an efficient scavenger of acrolein. Redox Rep. 2000;5(1):47\u20139. https:\/\/doi.org\/10.1179\/rer.2000.5.1.47.","journal-title":"Redox Rep"},{"issue":"1","key":"239_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0014-2999(98)00701-8","volume":"361","author":"L Bang","year":"1998","unstructured":"Bang L, Nielsen-Kudsk JE, Gruhn N, Trautner S, Theilgaard SA, Olesen SP, et al. Hydralazine-induced vasodilation involves opening of high conductance Ca2+\u2212activated K+ channels. Eur J Pharmacol. 1998;361(1):43\u20139. https:\/\/doi.org\/10.1016\/S0014-2999(98)00701-8.","journal-title":"Eur J Pharmacol"},{"issue":"4800","key":"239_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/bmj.1.4800.27","volume":"1","author":"MA Khan","year":"1953","unstructured":"Khan MA. Effect of hydralazine in hypertension. Br Med J. 1953;1(4800):27\u20139. https:\/\/doi.org\/10.1136\/bmj.1.4800.27.","journal-title":"Br Med J"},{"issue":"2","key":"239_CR26","first-page":"199","volume":"32","author":"RB Pandit","year":"1984","unstructured":"Pandit RB. Long term propranolol and hydralazine in hypertension. J Assoc Physicians India. 1984;32(2):199\u2013202.","journal-title":"J Assoc Physicians India"},{"issue":"2","key":"239_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3109\/15563657208991000","volume":"5","author":"FW Oehme","year":"1972","unstructured":"Oehme FW. British anti-lewisite (BAL), the classic heavy metal antidote. Clin Toxicol. 1972;5(2):215\u201322. https:\/\/doi.org\/10.3109\/15563657208991000.","journal-title":"Clin Toxicol"},{"issue":"24","key":"239_CR28","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJM195112132452401","volume":"245","author":"D Denny-Brown","year":"1951","unstructured":"Denny-Brown D, Porter H. The effect of BAL (2,3-dimercaptopropanol) on hepatolenticular degeneration (Wilson's disease). N Engl J Med. 1951;245(24):917\u201325.","journal-title":"N Engl J Med"},{"issue":"5","key":"239_CR29","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/jnc.14025","volume":"141","author":"R Tian","year":"2017","unstructured":"Tian R, Shi R. Dimercaprol is an acrolein scavenger that mitigates acrolein-mediated PC-12 cells toxicity and reduces acrolein in rat following spinal cord injury. J Neurochem. 2017;141(5):708\u201320. https:\/\/doi.org\/10.1111\/jnc.14025.","journal-title":"J Neurochem"},{"issue":"4","key":"239_CR30","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/WCO.0000000000000711","volume":"32","author":"K Rukavina","year":"2019","unstructured":"Rukavina K, Leta V, Sportelli C, Buhidma Y, Duty S, Malcangio M, et al. Pain in Parkinson's disease: new concepts in pathogenesis and treatment. Curr Opin Neurol. 2019;32(4):579\u201388. https:\/\/doi.org\/10.1097\/WCO.0000000000000711.","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"239_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.neures.2013.05.003","volume":"76","author":"Y Zengin-Toktas","year":"2013","unstructured":"Zengin-Toktas Y, Ferrier J, Durif F, Llorca PM, Authier N. Bilateral lesions of the nigrostriatal pathways are associated with chronic mechanical pain hypersensitivity in rats. Neurosci Res. 2013;76(4):261\u20134. https:\/\/doi.org\/10.1016\/j.neures.2013.05.003.","journal-title":"Neurosci Res"},{"key":"239_CR32","doi-asserted-by":"crossref","first-page":"174480691769152","DOI":"10.1177\/1744806917691525","volume":"13","author":"CT Wang","year":"2017","unstructured":"Wang CT, Mao CJ, Zhang XQ, Zhang CY, Lv DJ, Yang YP, et al. Attenuation of hyperalgesia responses via the modulation of 5-hydroxytryptamine signalings in the rostral ventromedial medulla and spinal cord in a 6-hydroxydopamine-induced rat model of Parkinson's disease. Mol Pain. 2017;13:1744806917691525.","journal-title":"Mol Pain"},{"issue":"1","key":"239_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-019-0104-6","volume":"6","author":"Y Buhidma","year":"2020","unstructured":"Buhidma Y, Rukavina K, Chaudhuri KR, Duty S. Potential of animal models for advancing the understanding and treatment of pain in Parkinson's disease. NPJ Parkinson Dis. 2020;6(1):1. https:\/\/doi.org\/10.1038\/s41531-019-0104-6.","journal-title":"NPJ Parkinson Dis"},{"key":"239_CR34","doi-asserted-by":"crossref","unstructured":"Lin Y, Chen Z, Tang J, Cao P, Shi R. Acrolein contributes to the neuropathic pain and neuron damage after ischemic-reperfusion spinal cord injury. Neuroscience. 2018;384:120\u201330.\u00a0","DOI":"10.1016\/j.neuroscience.2018.05.029"},{"key":"239_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jns.2017.05.039","volume":"379","author":"B Butler","year":"2017","unstructured":"Butler B, Acosta G, Shi R. Exogenous Acrolein intensifies sensory hypersensitivity after spinal cord injury in rat. J Neurol Sci. 2017;379:29\u201335. https:\/\/doi.org\/10.1016\/j.jns.2017.05.039.","journal-title":"J Neurol Sci"},{"issue":"2","key":"239_CR36","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/jnc.13639","volume":"138","author":"Z Chen","year":"2016","unstructured":"Chen Z, Park J, Butler B, Acosta G, Vega-Alvarez S, Zheng L, et al. Mitigation of sensory and motor deficits by acrolein scavenger phenelzine in a rat model of spinal cord contusive injury. J Neurochem. 2016;138(2):328\u201338. https:\/\/doi.org\/10.1111\/jnc.13639.","journal-title":"J Neurochem"},{"issue":"5","key":"239_CR37","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/jnc.13352","volume":"135","author":"J Park","year":"2015","unstructured":"Park J, Zheng L, Acosta G, Vega-Alvarez S, Chen Z, Muratori B, et al. Acrolein contributes to TRPA1 up-regulation in peripheral and central sensory hypersensitivity following spinal cord injury. J Neurochem. 2015;135(5):987\u201397. https:\/\/doi.org\/10.1111\/jnc.13352.","journal-title":"J Neurochem"},{"issue":"5","key":"239_CR38","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/jnc.12500","volume":"128","author":"MR Due","year":"2014","unstructured":"Due MR, Park J, Zheng L, Walls M, Allette YM, White FA, et al. Acrolein involvement in sensory and behavioral hypersensitivity following spinal cord injury in the rat. J Neurochem. 2014;128(5):776\u201386. https:\/\/doi.org\/10.1111\/jnc.12500.","journal-title":"J Neurochem"},{"issue":"6","key":"239_CR39","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.cell.2006.02.023","volume":"124","author":"DM Bautista","year":"2006","unstructured":"Bautista DM, Jordt SE, Nikai T, Tsuruda PR, Read AJ, Poblete J, et al. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell. 2006;124(6):1269\u201382. https:\/\/doi.org\/10.1016\/j.cell.2006.02.023.","journal-title":"Cell."},{"issue":"33","key":"239_CR40","doi-asserted-by":"publisher","first-page":"13519","DOI":"10.1073\/pnas.0705923104","volume":"104","author":"M Trevisani","year":"2007","unstructured":"Trevisani M, Siemens J, Materazzi S, Bautista DM, Nassini R, Campi B, et al. 4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1. Proc Natl Acad Sci U S A. 2007;104(33):13519\u201324. https:\/\/doi.org\/10.1073\/pnas.0705923104.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"239_CR41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.neulet.2013.02.066","volume":"543","author":"S Ayton","year":"2013","unstructured":"Ayton S, George JL, Adlard PA, Bush AI, Cherny RA, Finkelstein DI. The effect of dopamine on MPTP-induced rotarod disability. Neurosci Lett. 2013;543:105\u20139. https:\/\/doi.org\/10.1016\/j.neulet.2013.02.066.","journal-title":"Neurosci Lett"},{"issue":"1","key":"239_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","volume":"53","author":"SR Chaplan","year":"1994","unstructured":"Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53(1):55\u201363. https:\/\/doi.org\/10.1016\/0165-0270(94)90144-9.","journal-title":"J Neurosci Methods"},{"issue":"5","key":"239_CR43","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nrneurol.2009.50","volume":"5","author":"B Ford","year":"2009","unstructured":"Ford B. Parkinson disease: pain in Parkinson disease: the hidden epidemic. Nat Rev Neurol. 2009;5(5):242\u20133. https:\/\/doi.org\/10.1038\/nrneurol.2009.50.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"239_CR44","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/j.1742-4658.2012.08491.x","volume":"279","author":"F Blandini","year":"2012","unstructured":"Blandini F, Armentero MT. Animal models of Parkinson's disease. FEBS J. 2012;279(7):1156\u201366. https:\/\/doi.org\/10.1111\/j.1742-4658.2012.08491.x.","journal-title":"FEBS J"},{"key":"239_CR45","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.expneurol.2017.11.009","volume":"300","author":"JM Bonato","year":"2018","unstructured":"Bonato JM, Bassani TB, Milani H, Vital M, de Oliveira RMW. Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats. Exp Neurol. 2018;300:188\u2013200. https:\/\/doi.org\/10.1016\/j.expneurol.2017.11.009.","journal-title":"Exp Neurol"},{"key":"239_CR46","doi-asserted-by":"publisher","first-page":"101377","DOI":"10.1016\/j.redox.2019.101377","volume":"28","author":"A Farzam","year":"2020","unstructured":"Farzam A, Chohan K, Strmiskova M, Hewitt SJ, Park DS, Pezacki JP, et al. A functionalized hydroxydopamine quinone links thiol modification to neuronal cell death. Redox Biol. 2020;28:101377. https:\/\/doi.org\/10.1016\/j.redox.2019.101377.","journal-title":"Redox Biol"},{"issue":"16","key":"239_CR47","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670\u201383. https:\/\/doi.org\/10.1001\/jama.2014.3654.","journal-title":"JAMA."},{"issue":"7","key":"239_CR48","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1172\/JCI29178","volume":"116","author":"JM Savitt","year":"2006","unstructured":"Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest. 2006;116(7):1744\u201354. https:\/\/doi.org\/10.1172\/JCI29178.","journal-title":"J Clin Invest"},{"key":"239_CR49","doi-asserted-by":"publisher","first-page":"147251","DOI":"10.1155\/2014\/147251","volume":"2014","author":"S Montes","year":"2014","unstructured":"Montes S, Rivera-Mancia S, Diaz-Ruiz A, Tristan-Lopez L, Rios C. Copper and copper proteins in Parkinson's disease. Oxidative Med Cell Longev. 2014;2014:147251.","journal-title":"Oxidative Med Cell Longev"},{"key":"239_CR50","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.bcp.2017.12.001","volume":"148","author":"S Dichtl","year":"2018","unstructured":"Dichtl S, Haschka D, Nairz M, Seifert M, Volani C, Lutz O, et al. Dopamine promotes cellular iron accumulation and oxidative stress responses in macrophages. Biochem Pharmacol. 2018;148:193\u2013201. https:\/\/doi.org\/10.1016\/j.bcp.2017.12.001.","journal-title":"Biochem Pharmacol"},{"key":"239_CR51","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.nbd.2012.07.020","volume":"49","author":"CC Chen","year":"2013","unstructured":"Chen CC, Shih YY, Chang C. Dopaminergic imaging of nonmotor manifestations in a rat model of Parkinson's disease by fMRI. Neurobiol Dis. 2013;49:99\u2013106. https:\/\/doi.org\/10.1016\/j.nbd.2012.07.020.","journal-title":"Neurobiol Dis"},{"issue":"5","key":"239_CR52","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jpainsymman.2006.05.020","volume":"32","author":"MA Lee","year":"2006","unstructured":"Lee MA, Walker RW, Hildreth TJ, Prentice WM. A survey of pain in idiopathic Parkinson's disease. J Pain Symptom Manag. 2006;32(5):462\u20139. https:\/\/doi.org\/10.1016\/j.jpainsymman.2006.05.020.","journal-title":"J Pain Symptom Manag"},{"issue":"3","key":"239_CR53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.parkreldis.2003.12.001","volume":"10","author":"BH Quittenbaum","year":"2004","unstructured":"Quittenbaum BH, Grahn B. Quality of life and pain in Parkinson's disease: a controlled cross-sectional study. Parkinsonism Relat Disord. 2004;10(3):129\u201336. https:\/\/doi.org\/10.1016\/j.parkreldis.2003.12.001.","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 1","key":"239_CR54","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1002\/mds.22716","volume":"25","author":"B Ford","year":"2010","unstructured":"Ford B. Pain in Parkinson's disease. Mov Disord. 2010;25(Suppl 1):S98\u2013103. https:\/\/doi.org\/10.1002\/mds.22716.","journal-title":"Mov Disord"},{"issue":"32","key":"239_CR55","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.3969\/j.issn.1673-5374.2013.32.004","volume":"8","author":"N Ushio","year":"2013","unstructured":"Ushio N, Dai Y, Wang S, Fukuoka T, Noguchi K. Transient receptor potential channel A1 involved in calcitonin gene-related peptide release in neurons. Neural Regen Res. 2013;8(32):3013\u20139. https:\/\/doi.org\/10.3969\/j.issn.1673-5374.2013.32.004.","journal-title":"Neural Regen Res"},{"issue":"5","key":"239_CR56","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1165\/rcmb.2007-0130OC","volume":"37","author":"F Facchinetti","year":"2007","unstructured":"Facchinetti F, Amadei F, Geppetti P, Tarantini F, Di Serio C, Dragotto A, et al. \u03b1,\u03b2-unsaturated aldehydes in cigarette smoke release inflammatory mediators from human macrophages. Am J Respir Cell Mol Biol. 2007;37(5):617\u201323. https:\/\/doi.org\/10.1165\/rcmb.2007-0130OC.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"239_CR57","doi-asserted-by":"crossref","unstructured":"Gianaris A, Liu NK, Wang XF, Oakes E, Brenia J, Gianaris T, et al. Unilateral microinjection of acrolein into thoracic spinal cord produces acute and chronic injury and functional deficits. Neuroscience. 2016;326:84\u201394.\u00a0","DOI":"10.1016\/j.neuroscience.2016.03.054"},{"issue":"3","key":"239_CR58","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0304-3959(00)00409-7","volume":"90","author":"SK Jaaskelainen","year":"2001","unstructured":"Jaaskelainen SK, Rinne JO, Forssell H, Tenovuo O, Kaasinen V, Sonninen P, et al. Role of the dopaminergic system in chronic pain -- a fluorodopa-PET study. Pain. 2001;90(3):257\u201360. https:\/\/doi.org\/10.1016\/S0304-3959(00)00409-7.","journal-title":"Pain."},{"issue":"12","key":"239_CR59","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00415-009-0908-0","volume":"255","author":"HJ Kim","year":"2008","unstructured":"Kim HJ, Paek SH, Kim JY, Lee JY, Lim YH, Kim MR, et al. Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. J Neurol. 2008;255(12):1889\u201394. https:\/\/doi.org\/10.1007\/s00415-009-0908-0.","journal-title":"J Neurol"},{"key":"239_CR60","doi-asserted-by":"publisher","unstructured":"Kheradpezhouh E, Choy JMC, Daria VR, Arabzadeh E. TRPA1 expression and its functional activation in rodent cortex. Open Biol. 2017;7:160314. https:\/\/doi.org\/10.1098\/rsob.160314.","DOI":"10.1098\/rsob.160314"},{"issue":"1","key":"239_CR61","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12974-016-0557-z","volume":"13","author":"KI Lee","year":"2016","unstructured":"Lee KI, Lee HT, Lin HC, Tsay HJ, Tsai FC, Shyue SK, et al. Role of transient receptor potential ankyrin 1 channels in Alzheimer's disease. J Neuroinflammation. 2016;13(1):92. https:\/\/doi.org\/10.1186\/s12974-016-0557-z.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"239_CR62","doi-asserted-by":"publisher","first-page":"H889","DOI":"10.1152\/ajpheart.00106.2018","volume":"316","author":"DJ Conklin","year":"2019","unstructured":"Conklin DJ, Guo Y, Nystoriak MA, Jagatheesan G, Obal D, Kilfoil PJ, et al. TRPA1 channel contributes to myocardial ischemia-reperfusion injury. AM J Physiol-Heart C. 2019;316(4):H889\u2013H99. https:\/\/doi.org\/10.1152\/ajpheart.00106.2018.","journal-title":"AM J Physiol-Heart C"},{"issue":"1","key":"239_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12950-018-0204-9","volume":"15","author":"S Yin","year":"2018","unstructured":"Yin S, Zhang L, Ding L, Huang Z, Xu B, Li X, et al. Transient receptor potential ankyrin 1 (trpa1) mediates il-1beta-induced apoptosis in rat chondrocytes via calcium overload and mitochondrial dysfunction. J Inflamm. 2018;15(1):27. https:\/\/doi.org\/10.1186\/s12950-018-0204-9.","journal-title":"J Inflamm"},{"issue":"3","key":"239_CR64","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1523\/JNEUROSCI.4166-04.2005","volume":"25","author":"SR Kim","year":"2005","unstructured":"Kim SR, Lee DY, Chung ES, Oh UT, Kim SU, Jin BK. Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. J Neurosci. 2005;25(3):662\u201371. https:\/\/doi.org\/10.1523\/JNEUROSCI.4166-04.2005.","journal-title":"J Neurosci"},{"key":"239_CR65","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.tvjl.2016.11.016","volume":"219","author":"AM Sangster","year":"2017","unstructured":"Sangster AM, Zheng L, Bentley RT, Shi R, Packer RA. Urinary 3-hydroxypropyl mercapturic acid (3-HPMA) concentrations in dogs with acute spinal cord injury due to intervertebral disc herniation. Vet J. 2017;219:12\u20134. https:\/\/doi.org\/10.1016\/j.tvjl.2016.11.016.","journal-title":"Vet J"},{"issue":"3","key":"239_CR66","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3171\/2015.1.JNS141571","volume":"124","author":"MK Walls","year":"2016","unstructured":"Walls MK, Race N, Zheng L, Vega-Alvarez SM, Acosta G, Park J, et al. Structural and biochemical abnormalities in the absence of acute deficits in mild primary blast-induced head trauma. J Neurosurg. 2016;124(3):675\u201386. https:\/\/doi.org\/10.3171\/2015.1.JNS141571.","journal-title":"J Neurosurg"},{"issue":"1","key":"239_CR67","doi-asserted-by":"publisher","first-page":"10273","DOI":"10.1038\/s41598-018-28271-7","volume":"8","author":"D Garcia-Gonzalez","year":"2018","unstructured":"Garcia-Gonzalez D, Race NS, Voets NL, Jenkins DR, Sotiropoulos SN, Acosta G, et al. Cognition based bTBI mechanistic criteria; a tool for preventive and therapeutic innovations. Sci Rep. 2018;8(1):10273. https:\/\/doi.org\/10.1038\/s41598-018-28271-7.","journal-title":"Sci Rep"},{"key":"239_CR68","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.neuroscience.2010.11.018","volume":"173","author":"G Leung","year":"2011","unstructured":"Leung G, Sun W, Zheng L, Brookes S, Tully M, Shi R. Anti-acrolein treatment improves behavioral outcome and alleviates myelin damage in experimental autoimmune enchephalomyelitis mouse. Neurosci. 2011;173:150\u20135. https:\/\/doi.org\/10.1016\/j.neuroscience.2010.11.018.","journal-title":"Neurosci."},{"issue":"10","key":"239_CR69","doi-asserted-by":"publisher","first-page":"20037","DOI":"10.3390\/ijms141020037","volume":"14","author":"M Tully","year":"2013","unstructured":"Tully M, Shi R. New insights in the pathogenesis of multiple sclerosis\u2014role of Acrolein in neuronal and myelin damage. Int J Mol Sci. 2013;14(10):20037\u201347. https:\/\/doi.org\/10.3390\/ijms141020037.","journal-title":"Int J Mol Sci"},{"key":"239_CR70","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3389\/fneur.2018.00420","volume":"9","author":"M Tully","year":"2018","unstructured":"Tully M, Tang J, Zheng L, Acosta G, Tian R, Hayward L, et al. Systemic Acrolein elevations in mice with experimental autoimmune encephalomyelitis and patients with multiple sclerosis. Front Neurol. 2018;9:420. https:\/\/doi.org\/10.3389\/fneur.2018.00420.","journal-title":"Front Neurol"},{"issue":"2","key":"239_CR71","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1046\/j.1471-4159.1999.0720751.x","volume":"72","author":"NY Calingasan","year":"1999","unstructured":"Calingasan NY, Uchida K, Gibson GE. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J Neurochem. 1999;72(2):751\u20136. https:\/\/doi.org\/10.1046\/j.1471-4159.1999.0720751.x.","journal-title":"J Neurochem"},{"issue":"2","key":"239_CR72","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0197-4580(00)00235-9","volume":"22","author":"MA Lovell","year":"2001","unstructured":"Lovell MA, Xie C, Markesbery WR. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging. 2001;22(2):187\u201394. https:\/\/doi.org\/10.1016\/S0197-4580(00)00235-9.","journal-title":"Neurobiol Aging"},{"issue":"8","key":"239_CR73","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.neurobiolaging.2005.06.004","volume":"27","author":"TI Williams","year":"2006","unstructured":"Williams TI, Lynn BC, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging. 2006;27(8):1094\u20139. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2005.06.004.","journal-title":"Neurobiol Aging"},{"issue":"13","key":"239_CR74","first-page":"3577","volume":"52","author":"SM Cohen","year":"1992","unstructured":"Cohen SM, Garland EM, St John M, Okamura T, Smith RA. Acrolein initiates rat urinary bladder carcinogenesis. Cancer Res. 1992;52(13):3577\u201381.","journal-title":"Cancer Res"},{"issue":"42","key":"239_CR75","doi-asserted-by":"publisher","first-page":"15404","DOI":"10.1073\/pnas.0607031103","volume":"103","author":"Z Feng","year":"2006","unstructured":"Feng Z, Hu W, Hu Y, Tang MS. Acrolein is a major cigarette-related lung cancer agent: preferential binding at p53 mutational hotspots and inhibition of DNA repair. Proc Natl Acad Sci U S A. 2006;103(42):15404\u20139. https:\/\/doi.org\/10.1073\/pnas.0607031103.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"50","key":"239_CR76","doi-asserted-by":"publisher","first-page":"50346","DOI":"10.1074\/jbc.M309057200","volume":"278","author":"Y Kawai","year":"2003","unstructured":"Kawai Y, Furuhata A, Toyokuni S, Aratani Y, Uchida K. Formation of acrolein-derived 2\u2032-deoxyadenosine adduct in an iron-induced carcinogenesis model. J Biol Chem. 2003;278(50):50346\u201354. https:\/\/doi.org\/10.1074\/jbc.M309057200.","journal-title":"J Biol Chem"},{"issue":"5","key":"239_CR77","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S0891-5849(02)00807-9","volume":"33","author":"TJ Montine","year":"2002","unstructured":"Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ, et al. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med. 2002;33(5):620\u20136. https:\/\/doi.org\/10.1016\/S0891-5849(02)00807-9.","journal-title":"Free Radic Biol Med"},{"issue":"8","key":"239_CR78","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1021\/es010262g","volume":"36","author":"R Magnusson","year":"2002","unstructured":"Magnusson R, Nilsson C, Andersson B. Emissions of aldehydes and ketones from a two-stroke engine using ethanol and ethanol-blended gasoline as fuel. Environ Sci Technol. 2002;36(8):1656\u201364. https:\/\/doi.org\/10.1021\/es010262g.","journal-title":"Environ Sci Technol"},{"issue":"17","key":"239_CR79","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1021\/es071718i","volume":"42","author":"TW Hesterberg","year":"2008","unstructured":"Hesterberg TW, Lapin CA, Bunn WB. A comparison of emissions from vehicles fueled with diesel or compressed natural gas. Environ Sci Technol. 2008;42(17):6437\u201345. https:\/\/doi.org\/10.1021\/es071718i.","journal-title":"Environ Sci Technol"},{"issue":"3","key":"239_CR80","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.cbi.2009.12.006","volume":"183","author":"PC Burcham","year":"2010","unstructured":"Burcham PC, Raso A, Thompson CA. Toxicity of smoke extracts towards A549 lung cells: role of acrolein and suppression by carbonyl scavengers. Chem Biol Interact. 2010;183(3):416\u201324. https:\/\/doi.org\/10.1016\/j.cbi.2009.12.006.","journal-title":"Chem Biol Interact"},{"issue":"6 Suppl","key":"239_CR81","doi-asserted-by":"publisher","first-page":"1490S","DOI":"10.1093\/ajcn\/62.6.1490S","volume":"62","author":"JP Eiserich","year":"1995","unstructured":"Eiserich JP, van der Vliet A, Handelman GJ, Halliwell B, Cross CE. Dietary antioxidants and cigarette smoke-induced biomolecular damage: a complex interaction. Am J Clin Nutr. 1995;62(6 Suppl):1490S\u2013500S. https:\/\/doi.org\/10.1093\/ajcn\/62.6.1490S.","journal-title":"Am J Clin Nutr"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-021-00239-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-021-00239-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-021-00239-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T04:03:29Z","timestamp":1619582609000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-021-00239-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["239"],"URL":"https:\/\/doi.org\/10.1186\/s40035-021-00239-0","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"11 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Riyi Shi is the co-founder of Neuro Vigor, a star-up company with business interests of developing effective therapies for CNS neurodegenerative diseases and trauma.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}